Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Rhea-AI Summary

Oragenics (NYSE American: OGEN) reported continued progress in its Phase IIa feasibility trial of ONP-002, its intranasal candidate for mild traumatic brain injury, with nine participants dosed across three active Australian sites (Alfred Health, Mackay and Royal Adelaide Hospital). The company received FDA feedback to its July 2026 Type B meeting briefing package and remains focused on submitting an IND application by year-end 2026. Oragenics also disclosed a NYSE American deficiency letter dated August 26, 2026, stating it is not in compliance with stockholders’ equity requirements under Sections 1003(a)(ii) and 1003(a)(iii). Oragenics has 45 days to submit a compliance plan, after which it may continue trading during a cure period, but could face delisting procedures if it fails to regain compliance by February 25, 2028.

Positive

• Nine participants dosed in ONP-002 Phase IIa feasibility trial in Australia
• Activation of three Australian clinical sites for ONP-002 (Alfred Health, Mackay, Royal Adelaide Hospital)
• Ongoing FDA interaction supports goal to file IND by end of 2026

Negative

• NYSE American deficiency letter for non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) stockholders’ equity standards
• Potential NYSE American delisting risk if compliance not regained by February 25, 2028

Argus Aug 31 session 3 alerts

-2.75% close to close 1.8x rel. volume Open Argus

Details

News Market Reaction – OGEN

$2.57M Market Cap

In the Aug 31 session, OGEN declined 2.75%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status.

Clinical & Regulatory Momentum Continues

Oragenics continues to advance ONP-002, its lead intranasal candidate for mTBI (concussion), through its Phase IIa feasibility trial in Australia. To date, the Company has dosed nine participants across its active trial sites.

• Three Australian clinical sites now active: Alfred Health, Mackay, and Royal Adelaide Hospital
• Nine participants dosed to date
• Continued site-level enrollment support and monitoring underway across all active sites
  

U.S. Regulatory Update

The Company has received responses from the U.S. Food and Drug Administration (FDA) related to its Type B meeting request briefing package, submitted in July 2026. Oragenics is currently reviewing these items and remains focused on its goal of submitting an Investigational New Drug (IND) application by the end of 2026.

NYSE American Listing Status

On August 26, 2026, Oragenics received a deficiency letter from NYSE American LLC notifying the Company that it is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’ equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.. This is the same continued listing standard the Company previously addressed and regained compliance with in October 2025.

Under NYSE American rules, the Company has 45 days from receipt of the deficiency letter within which to submit a plan to regain compliance with the continued listing standards. If the plan is accepted, the Company will continue its listing during a cure period, subject to periodic review by NYSE American staff. While the Company intends to submit a compliance plan to NYSE American within the required timeframe and will endeavor to undertake a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements and believes that with continued execution of its clinical and regulatory milestones, it will regain full compliance with continued listing requirements, there can be no assurances in this regard. If the Plan is not timely submitted, or not accepted, or is accepted but the Company is not in compliance with the continued listing standards by February 25, 2028 or if the Company does not make progress consistent with the Plan during the Plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide.

Looking Ahead

Oragenics remains focused on execution across its clinical, regulatory, and corporate objectives: continued Phase IIa enrollment and dosing in Australia, advancing its U.S. IND submission, and building out its broader CNS pipeline. The Company believes its recent progress — including a third active Australian site, nine participants dosed, and constructive engagement with the FDA — reflects continued momentum toward its year-end goals.

"We're encouraged by the pace of enrollment in Australia and by the FDA's engagement on our Type B package," said Janet Huffman, Chief Executive Officer of Oragenics.

About Oragenics

Oragenics is a clinical-stage biopharmaceutical company pioneering brain-targeted therapeutics through its proprietary intranasal delivery technology. The Company's lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow. For more information, visit www.oragenics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company's ability to regain compliance with NYSE American continued listing standards, the timing and outcomes of clinical trials, the Company's regulatory strategy and anticipated IND submission, and the sufficiency of capital to fund operations. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's most recent Forms 10-K, 10-Q, and other filings with the SEC, available through EDGAR at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts

Investor Relations: irth Communications - IR@oragenics.com.com
Media Relations: irth Communications — IR@oragenics.com.com

FAQ

What clinical progress did Oragenics (OGEN) report for ONP-002 in August 2026?

Oragenics reported that nine participants have been dosed in its Phase IIa feasibility trial of ONP-002 in Australia. According to Oragenics, three clinical sites are now active, with ongoing site-level enrollment support and monitoring across Alfred Health, Mackay and Royal Adelaide Hospital.

What is the NYSE American listing issue disclosed by Oragenics (OGEN) on August 28, 2026?

Oragenics disclosed receiving a NYSE American deficiency letter on August 26, 2026, for not meeting stockholders’ equity requirements under Sections 1003(a)(ii) and 1003(a)(iii). According to Oragenics, this relates to minimum equity thresholds tied to multi-year operating or net losses.

How long does Oragenics (OGEN) have to regain NYSE American compliance after the August 2026 deficiency letter?

Oragenics has 45 days from August 26, 2026, to submit a compliance plan to NYSE American. According to Oragenics, if the plan is accepted, the company can continue listing during a cure period, with a latest compliance deadline of February 25, 2028.

Could Oragenics (OGEN) be delisted from NYSE American based on the August 2026 notice?

Oragenics could face delisting if it fails to submit, gain approval for, or execute its compliance plan or regain compliance by February 25, 2028. According to Oragenics, non-compliance with the plan’s milestones may also trigger delisting procedures under the NYSE American Company Guide.

What are Oragenics’ (OGEN) next regulatory milestones for ONP-002 after the August 2026 FDA feedback?

Following FDA responses to its Type B meeting request package submitted in July 2026, Oragenics is reviewing the feedback. According to Oragenics, the company remains focused on submitting an Investigational New Drug (IND) application for ONP-002 by the end of 2026.

What strategic objectives is Oragenics (OGEN) focusing on after its August 28, 2026 update?

Oragenics is prioritizing continued Phase IIa enrollment and dosing in Australia, advancing its U.S. IND submission for ONP-002, and expanding its broader CNS pipeline. According to Oragenics, these clinical and regulatory milestones are central to its efforts to regain full NYSE American compliance.